Many oral, small-molecule drugs are substrates for cytochrome P450 3A (CYP3A) metabolic enzymes, including anticancer agents used to treat patients with advanced cancer and other drugs that may be used to manage comorbid conditions [11]. The gene discussed is CYP3A4; the disease is cancer.